Corvus Pharmaceuticals, Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical products and clinical research.
The company announced in the following press release that, “The studies demonstrated that CPI-444, a selective and potent inhibitor of the adenosine A2A receptor, was effective in stimulating various immune cells, generating anti-tumor immunity, suppressing tumor growth and delaying tumor progression in animal models of cancer. ” Read the full article.
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel immuno-oncology therapies designed to harness the immune system to attack cancer cells. Its products include CPE-444, an orally administered antagonist of the adenosine A2A receptor; Adenosine production inhibitor; Adenosine A2B antagonist; and Interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. The company was founded by Richard A. Miller, Leiv Lea, and Joseph J. Buggy in January 27, 2014 and is headquartered in Burlingame, CA. [Source: MarketWatch]
Company Website: http://www.corvuspharma.com